EHN Canada’s new Eating Disorders Program, launching March 1, is helping those turned away by public healthcare option
EHN Canada’s new Eating Disorders Program, launching March 1, is helping those turned away by public healthcare options TORONTO, Feb. 23, 2021 /CNW/ – Bellwood Health Services, part of the EHN Canada nationwide network of premier treatment centres, is offering a new program designed to treat both eating disorders and concurrent mental health and addiction … Continue reading EHN Canada’s new Eating Disorders Program, launching March 1, is helping those turned away by public healthcare option
Drug treatment expert says Columbia professor who brags about using heroin should be fired
Drug treatment expert says Columbia professor who brags about using heroin should be fired***Members of the media interested in interviewing an addiction recovery expert from Footprints Beachside Recovery Center are encouraged to contact James Judge at 727.463.1295 or jpjudge@judgepr.com*** TREASURE ISLAND, Fla. – The founder of Footprints Beachside Recovery Center in Treasure Island had strong words for a … Continue reading Drug treatment expert says Columbia professor who brags about using heroin should be fired
Powerful True Story Inspires Others to Seek Adventure, Turn Each Day into a Gift
Powerful True Story Inspires Others to Seek Adventure, Turn Each Day into a Gift Fort Wayne, IN, February 23, 2021 — Brittany Moser’s short life was not defined by how she died, but rather, by how she lived each day to the fullest and the profound impact she had on those around her. Brittany died from … Continue reading Powerful True Story Inspires Others to Seek Adventure, Turn Each Day into a Gift
Health Canada approves DUPIXENT® (dupilumab injection) as the first biologic for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years
Health Canada approves DUPIXENT® (dupilumab injection) as the first biologic for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years DUPIXENT® is the only biologic medicine approved to treat atopic dermatitis for this patient population. Fifth indication for DUPIXENT® in Canada following approvals for moderate-to-severe atopic dermatitis in adults and adolescents, severe chronic … Continue reading Health Canada approves DUPIXENT® (dupilumab injection) as the first biologic for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years
KAATSU and PEAR Sports Partner to Develop a Dynamic App for Recovery, Rehabilitation and Performance Benefits
KAATSU and PEAR Sports Partner to Develop a Dynamic App for Recovery, Rehabilitation and Performance Benefits The pioneer and gold standard in Blood Flow Restriction technology offers instructional app to make KAATSU equipment and protocols more accessible and easy-to-use Newport Beach, California – February 23, 2021 –PEAR Sports and KAATSU Global have partnered to develop KAATSUfit, built by PEAR. This … Continue reading KAATSU and PEAR Sports Partner to Develop a Dynamic App for Recovery, Rehabilitation and Performance Benefits
